Key Developments: Diagnos Inc (DGNOF.PK)
0.11USD
20 Feb 2013
$-0.00 (-0.87%)
$0.12
$0.11
$0.11
$0.11
1,500
7,200
$0.25
$0.09
Latest Key Developments (Source: Significant Developments)
Diagnos Inc Announces Agreement To Sell Royalty Interest With Everton Resources Inc
Diagnos Inc announced that it has entered into an agreement with Everton Resources Inc whereby Everton will purchase DIAGNOS 2% Net Smelter Return royalty interest on the Labrador Trough gold, nickel, copper and zinc properties. On February 28, 2013 DIAGNOS sold Net Smelter Royalty of 2% to Everton on Labrador Trough gold, nickel, copper and zinc properties. Everton has acquired all of Diagnos' rights, title and interest to the royalty on these properties in exchange for 2,000,000 common shares and 500,000 common share purchase options. Each option will allow DIAGNOS to purchase an additional common share in Everton at $0.10 until five years from the date of grant. Full Article
Dundee Corp Acquires Further Interest In Diagnos Inc
Dundee Corp announced that it has acquired 6,000,000 units (Units) of Diagnos Inc. (Diagnos) in a private placement at a price of $0.10 per Unit. Each Unit consists of one common share in the capital of Diagnos and one common share purchase warrant (Warrant). Each Warrant entitles the holder to purchase one common share at the price of $0.15 for a period of 18 months. Dundee owns a position in Diagnos representing an approximate 14.98% interest or 22.96% assuming the exercise of all Warrants. Full Article
Diagnos Inc Announces Closing Of Private Placement
Diagnos Inc announced that it has closed its non-brokered private placement initially announced January 17th, 2013, consisting of 14,000,000 units (Units) issued at $0.10 per Unit, for gross proceeds of $1,400,000. Each Unit is comprised of one Common Share and one Common Share purchase warrant (Warrant). Each Warrant entitles its holder to acquire one Common Share at a price of $0.15 at any time during the 18 months following the closing date. The proceeds of the private placement will be mainly used to fund business development of the healthcare services and to fund product development with regards to the healthcare line of business. The securities issued in connection with this private placement are subject to a 4-month hold period expiring on June 8, 2013 in compliance with the policies of the TSX Venture Exchange and applicable securities legislation. Full Article
Diagnos Inc Announces Private Placement
Diagnos Inc announced that it has arranged a non-brokered private placement consisting of up to 14,000,000 units (Units) to be issued at $0.10 per Unit, for gross proceeds of $1,400,000. The proceeds of the private placement will be mainly used to fund business development of the healthcare services and to fund product development with regards to the healthcare line of business. Full Article
Diagnos Inc Announces Contract With Novartis Pharma AG
Diagnos Inc announced the signing of an agreement with Novartis Pharma AG, for the continuation and expansion of joint deployment and usage of CARA in the United Arab Emirates. Full Article
Diagnos Inc Acquires 1,193 New Additional Claims With Ontario Partner For Plan Nord In Province Of Quebec
Diagnos Inc announced the acquisition of 1,193 additional claims in the Plan Nord in the province of Quebec. Based on the press release dated August, 22, 2012 announcing the acquisition of 2,969 claims, to date DIAGNOS has acquired with its Ontario partner 4,162 claims in a project covering more than 304,000 square kilometers. DIAGNOS has used its proprietary Computer Aided Resource Detection System (CARDS) to target the mineral potential of the remote, sparsely staked northern portion of the province of Quebec. The work consisted of compiling, processing, and merging available geological, geochemical, geophysical, and topographical data as well as satellite imagery of the area. Terms of the transaction were not disclosed. Full Article
Diagnos Inc Signs First Clinical Client Contract in Vietnam for Diabetic Retinopathy Screening Using CARA
Diagnos Inc announced that it has signed a services contract with Vung Tau Ophthalmological Clinic, Vung Tau, VietNam, for diabetic retinopathy screening using CARA. CARA's local representative in VietNam, Alphi Investment (ALPHI) was instrumental in concluding the agreement. Full Article
Votorantim Will Use Services Of Diagnos Inc In Bathurst Mining Camp, New Brunswick
DIAGNOS inc announced that its CARDS technology will be used by Votorantim Metals Canada Inc. in the Bathurst Mining Camp, New Brunswick. The Bathurst Mining Camp (BMC) occupies a roughly circular area of approximately 70 km diameter in the Miramichi Highlands of northern New Brunswick. The area is host to some 46 mineral deposits with known resources and another hundred mineral occurrences, all hosted by Cambro-Ordovician rocks that were deposited in an ensialic back-arc basin. Full Article
Diagnos Inc Expands Agreement With Oftalmolaser de Mexico To Serve The Mexican Diabetes Association
Diagnos Inc announced the expansion of a diabetic retinopathy screening program with Mexican representative Canamexport and partner OFTALMOLASER DE MEXICO S.A. DE C.V. (Oftalmolaser), the medical subsidiary of GRUPO DEVLYN, S.A. De C.V. (Devlyn) to serve the Mexican Diabetes Association (Asociacion Mexicana de Diabetes). Under the terms of the expanded service agreement, DIAGNOS, and Oftalmolaser will offer DIAGNOS' Computer Assisted Retinal Analysis (CARA) technology in the Mexican Diabetes Association's clinics in Mexico. The service will include automated image processing (enhancement and analysis). Full Article
Diagnos Inc Announces Sale of 22 Concessions To Threegold Resources Inc.
Diagnos Inc announced the sale of its Collines Bearn and Dalquier properties to Threegold Resources inc., located directly beside Threegold's Rousseau West property. Those properties are found approximately 85 km from the city of Rouyn Noranda and 13 km from the city of Amos in Abitibi and correspond to 22 mining titles on a map totaling 1,282 hectares. Under the provisions of the purchase agreement, Threegold Resources will acquire 100% of the concessions by making cash payment of $10,000 and by issuing 200,000 common shares of Threegold Resources on behalf of DIAGNOS. Also, a 2% royalty on the net return of the smelting revenues associated with the minerals and concentrates to be extracted from the concessions will be perceived by DIAGNOS. The purchase agreement stipulates that Threegold Resources may, at any time, reduce the royalty from 2% to 1% by paying DIAGNOS $1,000,000 in cash. Full Article
Earnings vs. 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
